Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Synopsis

Accuracy of Diagnosis of Human Granulocytic Anaplasmosis in China

Article Metrics
6
citations of this article
EID Journal Metrics on Scopus
Gary P. WormserComments to Author 
Author affiliation: New York Medical College, Valhalla, New York, USA

Cite This Article

Abstract

In 2008, human granulocytic anaplasmosis (HGA) was reported from China. However, the clinical and laboratory findings, including reports of nosocomial transmission, were inconsistent with those reported for HGA in the United States. In 2012, it was demonstrated that the patients described in the 2008 report had all been infected with a newly discovered bunyavirus, severe fever with thrombocytopenia syndrome virus, which causes an illness with the same clinical features described for the patients in the 2008 report. This finding raises the question of HGA misdiagnosis in China and establishes the need for further studies to determine whether HGA occurs there.

The first clinical report of human granulocytic anaplasmosis (HGA) in China was published in 2008 (1). This publication was also the first and only report claiming human-to-human transmission of Anaplasma phagocytophilum (or, to my knowledge, of any rickettsial agent in the absence of a blood transfusion or a needlestick) and is frequently cited in articles on tickborne infections (2,3).

To determine the accuracy of the report from China, I compared certain clinical and laboratory features of the 9 laboratory-confirmed cases of HGA in that outbreak (all secondary case-patients were claimed to have been infected by the index patient) (1) with 44 culture-confirmed cases of HGA reported from a study conducted in the United States (4) (Table 1). The 9 China cases differed from the 44 US cases in that the patients from China were significantly less likely to report headache but significantly more likely to have diarrhea, leukopenia, severe leukopenia (<3,000 leukocytes/mm3), and thrombocytopenia (including more severe thrombocytopenia of <100,000 platelets/mm3). As was pointed out in the editorial that accompanied the report of HGA in China (5), other noteworthy differences were observed between the HGA patients in China and those in the United States. One of these differences was relative bradycardia in all 9 patients in China (1), a finding never reported for HGA in the United States. Another difference was convalescent antibody titers against A. phagocytophilum of <1:256 for all 9 patients in China, with testing performed by using an IgG immunofluorescent antibody kit (Focus Diagnostics, Cypress, CA, USA) (1), whereas titers of >1:640 were documented for ≈95% of 44 culture-positive HGA patients in the United States (4). In addition, for none of the 9 China patients were morulae observed on blood smear, despite the fact that no patient had received a tetracycline antimicrobial drug, and all patients were said to be positive for A. phagocytophilum DNA according to PCR (1). In contrast, morulae were seen for 34 (77.3%) of the 44 culture-positive US HGA patients (4). Furthermore, in the China case series, sequencing of the groEL gene product amplified by nested PCR indicated that the sequence was more similar to that of strains of A. phagocytophilum from the United States than from China, consistent with the occurrence of laboratory contamination. Nested PCR testing is prone to contamination, and the increased sensitivity afforded by this testing method is usually unnecessary when bacteria are numerous enough to be visualized by microscopy, as would be anticipated for patients with HGA (6).

The reported nosocomial transmission of A. phagocytophilum, in conjunction with the atypical clinical and laboratory test results, already raised questions as to whether the diagnosis of HGA was correct when the article was published (5). A potential breakthrough in understanding what type of infection the index patient and the 9 secondary case-patients may have actually had occurred in April 2011, when Yu et al. identified a novel bunyavirus in parts of China that coincided geographically with the earlier report of nosocomial acquisition of HGA (7). On the basis of clinical data reported in the article about the initial discovery of this bunyavirus (7), plus other studies that followed (810), this tickborne bunyavirus was found to be responsible for a febrile illness associated with leukopenia, thrombocytopenia, and gastrointestinal manifestations. In addition, this virus has been repeatedly shown to be transmissible from person to person through mucocutaneous exposure to the blood of an infected patient (1117). Furthermore, relative bradycardia in persons with this infection has been reported (8). The bunyavirus is called severe fever with thrombocytopenia syndrome virus (SFTSV).

When the 9 HGA cases described in the initial report from China (1) were compared with the 81 cases of SFTSV infection described in the initial publication about this infection (7), no significant differences were found for any of the parameters assessed (Table 2). This similarity is in marked contrast to the differences found when compared with the 44 culture-confirmed HGA cases from the United States (Table 1) (4). SFTSV infection, however, has many distinctive features when compared with HGA in the United States (Table 3).

Thus, it is logical to ask if the 9 HGA case-patients plus the index patient originally reported in China (1) actually had SFTSV infection. Liu et al. raised this same question and in their article published in 2012 demonstrated convincingly (i.e., by reverse transcription PCR, serologic testing, or both) that the index patient and the 9 secondary case-patients were infected with SFTSV (11). The article did not report, however, the results of retesting of the patient specimens for A. phagocytophilum DNA. Thus, there are only 2 potential hypotheses: 1) that all of the patients in the original China case series reported to have had HGA actually had SFTSV infection and not HGA, or 2) that all of the patients were co-infected with SFTSV and A. phagocytophilum (18,19).

The former hypothesis seems much more plausible because of the inconsistency of the laboratory test results for HGA in China with what would have been expected for this infection in the United States, in conjunction with the unprecedented and unlikely nosocomial transmission of A. phagocytophilum (18). In addition, the latter potential conclusion seems less likely in that it would mean that all 9 secondary case-patients were simultaneously infected with both infectious agents, without even 1 person having only 1 of the 2 infections, which is highly improbable. Considering that 23%–45% of the contacts became infected, depending on the time frame and proximity of the exposure to the index patient (1), and assuming that neither of these infections would per se affect the likelihood of person-to-person transmission of the other infection, it would be very unlikely that all secondary case-patients would have been co-infected with both pathogens. Assuming a binomial distribution, the likelihood that this would have occurred by chance alone is <0.0008 (Paul Visintainer, pers. comm., 2016 Jul 8). It also seems implausible that the frequency of headache would have been so low among these 9 case-patients if they were actually co-infected with HGA (Table 1). Why would simultaneous infection with SFTSV reduce the frequency of headache in HGA-infected patients?

To establish the recently proposed hypothesis that the index patient was co-infected with A. phagocytophilum and SFTSV by a single tick bite (19), several key pieces of information are required. One is whether the Haemaphysalis longicornis ticks (the primary tick vector for SFTSV) (9) found in the specific area of the Anhui Province of China where the index patient resided are infected with pathogenic strains of A. phagocytophilum (5); if so, the frequency of co-infection with SFTSV should be determined. In addition, it would be essential to establish whether this species of tick is a competent vector for A. phagocytophilum (18,19).

Since 2008, additional case series of patients with HGA in China have been reported (2022). What is the accuracy of these HGA diagnoses? The clinical and laboratory features reported are rather atypical in comparison with those reported for US patients, including in certain case series a higher frequency of gastrointestinal symptoms, regional lymphadenopathy, hepatosplenomegaly, relative bradycardia, facial edema, proteinuria, elevated cardiac enzyme levels, bleeding, and death. Headache and myalgia were reported significantly less commonly in the case series of HGA in China than in the United States, whereas leukopenia and severe thrombocytopenia were reported significantly more frequently (Table 4) (4,2022). It is unlikely that the patients in these case series from China (2022) were actually infected with the novel Anaplasma species provisionally named A. capra because cytopenia is infrequent among patients infected with A. capra (23,24).

If the cases in the original article about nosocomial transmission were misdiagnosed as HGA (1), several cautions should ideally be exercised regarding the diagnosis of HGA in China, as well as in other geographic areas where HGA has not been previously diagnosed. One is that reliance on the US Centers for Disease Control and Prevention case definition of HGA in the United States, intended for surveillance purposes (25), may not be sufficient to justify a diagnosis of HGA in China at this time. Validation and standardization of the PCR testing methods for A. phagocytophilum used in China should be a priority. Furthermore, serologic titers of <1:640 should not be considered indicative of HGA infection (26). Low positive titers are common in China (up to 20%) (27) and in the United States (26) and by no means establish current or prior infection with A. phagocytophilum. Locally cultivated strains of A. phagocytophilum might be a preferred source of antigens for serologic testing. In addition, given the numerous well-documented examples of clinically misdiagnosed HGA in China before recognition of SFTSV infection (28), individual patient assessments and all newly published case series of HGA should include testing for this virus as well as for other relevant infections included in the differential diagnosis. To date, testing for SFTSV has not been reported in many of the published case series of HGA in China (2022). More emphasis should be placed on establishing the diagnosis of HGA by using the microbiological standard of culturing the organism (4), at least until other diagnostic modalities can be adequately validated. To my knowledge, a positive culture result has been obtained for only 4 reported cases of HGA in China (20).

In conclusion, HGA cases have been reported from China since 2008. The clinical and laboratory features, including the claim of nosocomial transmission, differ markedly from the overall features of this infection in the United States. In retrospect, some of the HGA case-patients in China seem to have been infected with the newly discovered bunyavirus, SFTSV. Thus, I recommend that further efforts be made to validate laboratory testing for HGA in China.

Dr. Wormser is chief of the Division of Infectious Diseases, vice chairman of the Department of Medicine, and professor of medicine, microbiology and immunology, and pharmacology at New York Medical College. He is also chief of the Section of Infectious Diseases at Westchester Medical Center and director and founder of the Lyme Disease Diagnostic Center. His main research interests are tickborne infections.

Top

Acknowledgments

I thank David Walker, Sam Telford, Nancy Joy, Julia Singer, Sophia Less, and Lisa Giarratano for their assistance.

I have received research grants from Immunetics, Inc.; Institute for Systems Biology; RareCyte, Inc.; and Quidel Corporation. I own equity in Abbott Laboratories, have served as an expert witness in malpractice cases involving Lyme disease, and am an unpaid board member of the American Lyme Disease Foundation.

Top

References

  1. Zhang  L, Liu  Y, Ni  D, Li  Q, Yu  Y, Yu  XJ, Nosocomial transmission of human granulocytic anaplasmosis in China. JAMA. 2008;300:226370.DOIPubMed
  2. Fang  L-Q, Liu  K, Li  X-L, Liang  S, Yang  Y, Yao  HW, Emerging tick-borne infections in mainland China: an increasing public health threat. Lancet Infect Dis. 2015;15:146779.DOIPubMed
  3. Bakken  JS, Dumler  JS. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2015;29:34155.DOIPubMed
  4. Wormser  GP, Aguero-Rosenfeld  ME, Cox  ME, Nowakowski  J, Nadelman  RB, Holmgren  D, Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early lyme disease. J Clin Microbiol. 2013;51:9548.DOIPubMed
  5. Krause  PJ, Wormser  GP. Nosocomial transmission of human granulocytic anaplasmosis? JAMA. 2008;300:23089.DOIPubMed
  6. Johnson  BJB, Pilgard  MA, Russell  TM. Assessment of new culture method for detection of Borrelia species from serum of lyme disease patients. J Clin Microbiol. 2014;52:7214.DOIPubMed
  7. Yu  X-J, Liang  M-F, Zhang  S-Y, Liu  Y, Li  JD, Sun  YL, Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364:152332.DOIPubMed
  8. Xu  B, Liu  L, Huang  X, Ma  H, Zhang  Y, Du  Y, Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus. PLoS Pathog. 2011;7:e1002369.DOIPubMed
  9. Liu  Q, He  B, Huang  S-Y, Wei  F, Zhu  X-Q. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014;14:76372.DOIPubMed
  10. Liu  S, Chai  C, Wang  C, Amer  S, Lv  H, He  H, Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics. Rev Med Virol. 2014;24:90102.DOIPubMed
  11. Liu  Y, Li  Q, Hu  W, Wu  J, Wang  Y, Mei  L, Person-to-person transmission of severe fever with thrombocytopenia syndrome virus. Vector Borne Zoonotic Dis. 2012;12:15660.DOIPubMed
  12. Bao  C-J, Guo  X-L, Qi  X, Hu  JL, Zhou  MH, Varma  JK, A family cluster of infections by a newly recognized bunyavirus in eastern China, 2007: further evidence of person-to-person transmission. Clin Infect Dis. 2011;53:120814.DOIPubMed
  13. Kim  WY, Choi  W, Park  S-W, Wang  EB, Lee  WJ, Jee  Y, Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea. Clin Infect Dis. 2015;60:16813.DOIPubMed
  14. Tang  X, Wu  W, Wang  H, Du  Y, Liu  L, Kang  K, Human-to-human transmission of severe fever with thrombocytopenia syndrome bunyavirus through contact with infectious blood. J Infect Dis. 2013;207:7369.DOIPubMed
  15. Gai  Z, Liang  M, Zhang  Y, Zhang  S, Jin  C, Wang  SW, Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact. Clin Infect Dis. 2012;54:24952.DOIPubMed
  16. Chen  H, Hu  K, Zou  J, Xiao  J. A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. Int J Infect Dis. 2013;17:e2068.DOIPubMed
  17. Jiang  XL, Zhang  S, Jiang  M, Bi  ZQ, Liang  MF, Ding  SJ, A cluster of person-to-person transmission cases caused by SFTS virus in Penglai, China. Clin Microbiol Infect. 2015;21:2749.DOIPubMed
  18. Wormser  GP. Human granulocytic anaplasmosis and Lyme disease. JAMA. 2016;316:989.DOIPubMed
  19. Liu  Y, Yu  X-J. Human granulocytic anaplasmosis and Lyme disease–reply. JAMA. 2016;316:99.DOIPubMed
  20. Zhang  L, Wang  G, Liu  Q, Chen  C, Li  J, Long  B, Molecular analysis of Anaplasma phagocytophilum isolated from patients with febrile diseases of unknown etiology in China. PLoS One. 2013;8:e57155.DOIPubMed
  21. Jiao  X-Y, Fan  Z-C, Li  Y-Z, Tang  Y-T, Ke  C-W. Clinical and laboratory features parameters of human granulocytic anaplasmosis (HGA) in patients admitted to hospital in Guangdong Province, China. Trop Doct. 2015;45:20913.DOIPubMed
  22. Li  H, Zhou  Y, Wang  W, Guo  D, Huang  S, Jie  S. The clinical characteristics and outcomes of patients with human granulocytic anaplasmosis in China. Int J Infect Dis. 2011;15:e85966.DOIPubMed
  23. Sun  X-F, Zhao  L, Wen  H-L, Luo  L-M, Yu  X-J. Anaplasma species in China. Lancet Infect Dis. 2015;15:12634.DOIPubMed
  24. Li  H, Zheng  Y-C, Ma  L, Jia  N, Jiang  BG, Jiang  RR, Human infection with a novel tick-borne Anaplasma species in China: a surveillance study. Lancet Infect Dis. 2015;15:66370.DOIPubMed
  25. Chapman  AS, Bakken  JS, Folk  SM, Paddock  CD, Bloch  KC, Krusell  A, ; Tickborne Rickettsial Diseases Working Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis—United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):127.PubMed
  26. Aguero-Rosenfeld  ME, Donnarumma  L, Zentmaier  L, Jacob  J, Frey  M, Noto  R, Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol. 2002;40:26125.DOIPubMed
  27. Zhang  S, Hai  R, Li  W. Li G, Lin G, He J et al. Seroprevalance of human granulocytic anaplasmosis in central and southeastern China. Am J Trop Med Hyg. 2009;81:293–5.
  28. Xie  Y-T, Lai  D-H, Liu  G-Y, Zhou  J-L, Lun  Z-R. Severe fever with thrombocytopenia syndrome in China. Lancet Infect Dis. 2015;15:145.DOIPubMed

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid2210.160161

Table of Contents – Volume 22, Number 10—October 2016

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Gary P. Wormser, New York Medical College, Division of Infectious Diseases, 40 Sunshine Cottage Rd, Skyline Office #2N-F05, Valhalla, NY 10595, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: September 26, 2016
Page updated: September 26, 2016
Page reviewed: September 26, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external